PRESS RELEASE

11 August 2022 07:30:00 CEST

Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting

Ascelia Pharma AB (publ) (ticker: ACE) today announced that results from the Orviglance® Food Effect Study have been accepted as an oral presentation at the world's largest radiology conference, RSNA. The conference will be held November 27 – December 1 in Chicago, Illinois.

The Food Effect Study evaluates the effect of food intake on absorption and signal intensity of Orviglance. The results, originally announced in May 2022, showed that intake of a light meal prior to Orviglance administration provides similar image MRI enhancement of the liver compared to a fasting condition. In line with previous studies, the data also confirmed robust image enhancement of the liver after Orviglance administration compared to an MRI image without a contrast agent.

"We are very pleased that the study has been selected as an oral paper presentation at the prestigious radiology conference RSNA. Avoiding a fasting condition improves the convenience for patients and ease in the administration of Orviglance in clinical practice. The results further support our previous findings on the ability to provide image enhancement to MRI scans with Orviglance," said Carl Bjartmar, Chief Medical Officer of Ascelia Pharma.

Title of presentation: Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific ContrastAgent: Orviglance (Manganese Chloride Tetrahydrate)

Timing of presentation: November 30, 3.00pm local time Chicago.

Contacts

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: 46 735 179 118

Mikael Widell, IR & Communications
Email: mw@ascelia.com
Tel: +46 703 11 99 60

About us

About Ascelia Pharma

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

About Orviglance (previously referred to as Mangoral)

Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

Attachments

Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting